Payment overview · 2025
General Payments
$308.43
14 reported records · 9 companies
Healthcare provider profile · identity verified
Ryan T Borrowman, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ST GEORGE, UT · NPI 1487001442
Verified facts
What the public records show
CMS Open Payments records show Ryan T Borrowman, NP-C received $308.43 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.94 | 21.4% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $62.88 | 20.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.50 | 14.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.02 | 12.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.24 | 7.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.68 | 6.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.75 | 6.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.04 | 6.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.38 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.43 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $62.88 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 371 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 103 |
| Lisinopril | Lisinopril | 332 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 95 |
| Losartan Potassium | Losartan Potassium | 265 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 59 |
| Metformin Hcl | Metformin Hcl | 176 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 55 |
| Trazodone Hcl | Trazodone Hcl | 168 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 157 | 52 |
| Tramadol Hcl | Tramadol Hcl | 154 | 47 |
| Furosemide | Furosemide | 146 | 54 |
| Simvastatin | Simvastatin | 145 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 49 |
| Alprazolam | Alprazolam | 142 | 25 |
| Gabapentin | Gabapentin | 142 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 42 |
| Celecoxib | Celecoxib | 130 | 52 |
| Meloxicam | Meloxicam | 110 | 37 |
| Potassium Chloride | Potassium Chloride | 103 | 41 |
| Spironolactone | Spironolactone | 100 | 36 |
| Estradiol | Estradiol | 98 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 56 |
| Testosterone Cypionate | Testosterone Cypionate | 84 | 33 |
| Jardiance | Empagliflozin | 78 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 30 |
| Eliquis | Apixaban | 74 | 20 |
| Lorazepam | Lorazepam | 73 | 18 |
| Ozempic | Semaglutide | 71 | 23 |
| Sertraline Hcl | Sertraline Hcl | 71 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 23 |
| Finasteride | Finasteride | 67 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 47 |
| Carvedilol | Carvedilol | 64 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 40 |
| Propranolol Hcl | Propranolol Hcl | 62 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 60 | 37 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 37 |
| Clonazepam | Clonazepam | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Famotidine | Famotidine | 50 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 15 |
| Atenolol | Atenolol | 48 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Temazepam | Temazepam | 45 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Allopurinol | Allopurinol | 43 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 16 |
| Prednisone | Prednisone | 40 | 29 |
| Bupropion Xl | Bupropion Hcl | 39 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 19 |
| Azithromycin | Azithromycin | 36 | 33 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | 11 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 26 |
| Metformin Hcl Er | Metformin Hcl | 34 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Acyclovir | Acyclovir | 29 | 12 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Fluconazole | Fluconazole | 27 | 15 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 14 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 13 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.43 · 14 records | ABBVIE INC. | JARDIANCE, NURTEC ODT, QULIPTA, SUBLOCADE, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VRAYLAR, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error